Loading...
•
Jun 30, 2023
ACADIA Q2 2023 Earnings Report
Acadia Pharmaceuticals reported strong Q2 2023 results driven by the successful launch of DAYBUE and continued growth of NUPLAZID.
Key Takeaways
Acadia Pharmaceuticals reported a net income of $1.1 million for the second quarter of 2023, driven by strong performances from both the DAYBUE and NUPLAZID franchises. Total net product sales were $165.2 million, with NUPLAZID contributing $142.0 million and DAYBUE contributing $23.2 million.
Total net product sales reached $165.2 million, reflecting growth from both NUPLAZID and DAYBUE.
DAYBUE launch is off to a highly successful start with broad demand.
NUPLAZID franchise is increasingly profitable and gaining market share.
Completed enrollment in Phase 3 clinical trial for negative symptoms of schizophrenia, with results expected in Q1 2024.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals provided financial guidance for the third quarter and full year of 2023.
Positive Outlook
- DAYBUE third quarter net sales in the range of $45 to $55 million.
- NUPLAZID full year net sales in the range of $530 to $545 million.
Challenges Ahead
- R&D expense in the range of $335 to $355 million, which has been adjusted for the $100 million upfront payment to Neuren in July for the expanded licensing agreement.
- SG&A expense range increased to $380 to $400 million due to higher operating costs as a result of favorable business performance, including employee retention costs as well as DAYBUE incentive compensation and investments in patient support services.
Revenue & Expenses
Visualization of income flow from segment revenue to net income